Patient Profile Tool

Answer a few questions to help identify whether your patient may be a candidate for TYVASO.

United Therapeutics does not provide medical advice. It is up to you as a healthcare professional to determine the best course of treatment for your patients.

Question

1
2
3
4
5
6
slideslide

Is your patient symptomatic on oral non-prostacyclin therapy?

|

ANSWER

Yes

Patients who are symptomatic on oral non-prostacyclin therapy may be candidates for TYVASO.1,2

TYVASO improved exercise ability in clinically stable patients on oral non-prostacyclin monotherapy.2

ANSWER

No

Patients who are asymptomatic may still be appropriate for TYVASO.1-4 Pulmonary arterial hypertension may be progressing even if patients do not appear symptomatic. Also recognize that patients may be asymptomatic until advanced vasculopathy is evident. Treating PAH sooner may make a difference.5

TYVASO improved exercise ability in clinically stable patients on oral non-prostacyclin monotherapy.1

References:

  1. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.
  2. TYVASO [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2017.

References:

  1. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.
  2. TYVASO [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2017.
  3. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009;120(11):992-1007.
  4. Klinger JR. Pulmonary arterial hypertension: monitoring the patient’s response to therapy, part 1. J Respir Dis.2009;30:1-11.
  5. Sitbon O, Galie N. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. Eur Respir Rev. 2010;19(118):272-278.

Question

1
2
3
4
5
6
slideslide

What is your patient’s 6-minute walk distance (6MWD)?

|

ANSWER

>440 m*:

Based on your patient’s 6MWD, your patient may be at low risk.1 6MWD is just one of the parameters to be evaluated. For a more accurate picture of risk, evaluate 6MWD along with other variables. Consider re-evaluating 6MWD along with other important parameters of risk/prognosis every 3 to 6 months.

6MWD is a proven prognostic factor in US-based REVEAL and European observational studies.2-4 In COMPERA and the French PAH registry, 6MWD was the most predictive parameter for long-term outcomes.

 

*In TRIUMPH, the mean baseline 6MWD in the TYVASO group was 346 m.5

ANSWER

165-440 m*:

Based on your patient’s 6MWD, your patient may be at intermediate risk and a candidate for TYVASO.1,2 Consider re-evaluating 6MWD along with other important parameters of risk/prognosis every 3 to 6 months.

6MWD is a proven prognostic factor in US-based REVEAL and European observational studies.3-5 In COMPERA and the French PAH registry, 6MWD was the most predictive parameter for long-term outcomes.

 

*In TRIUMPH, the mean baseline 6MWD in the TYVASO group was 346 m.6

ANSWER

<165 m:

Based on your patient’s 6MWD, your patient may be at high risk and may be appropriate for parenteral prostacyclin therapy.1,2 Patient could be considered for TYVASO if unwilling or unable to tolerate parenteral prostacyclin therapy.2 Consider re-evaluating 6MWD along with other important parameters of risk/prognosis every 3 to 6 months.

6MWD is a proven prognostic factor in US-based REVEAL and European observational studies.3-5 In COMPERA and the French PAH registry, 6MWD was the most predictive parameter for long-term outcomes.

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. [Published online ahead of print. Accessed July 19, 2019.] Chest. doi:10.1016/j.chest.2019.02.004.
  3. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2).
  4. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).
  5. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.

 

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. TYVASO [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2017.
  3. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. [Published online ahead of print. Accessed July 19, 2019.] Chest. doi:10.1016/j.chest.2019.02.004.
  4. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2).
  5. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).
  6. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565-586.
  3. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. [Published online ahead of print. Accessed July 19, 2019.] Chest. doi:10.1016/j.chest.2019.02.004.
  4. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2).
  5. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).

 

Question

1
2
3
4
5
6
slideslide

What is your patient’s NT-proBNP level?

NT-proBNP=N-terminal pro–B-type natriuretic peptide.

|

ANSWER

<300 ng/L*:

Based on your patient’s NT-proBNP level, your patient may be at low risk.1 NT-proBNP is just one of the parameters to be evaluated. For a more accurate picture of risk, evaluate NT-proBNP along with other variables. Consider re-evaluating NT-proBNP along with other important parameters of risk/prognosis every 3 to 6 months.

NT-proBNP is one of the assessments that can help predict long-term treatment outcomes.2-4 NT-proBNP is a proven prognostic factor (or predictor of risk) in US-based REVEAL and European observational studies.

 

*In TRIUMPH, baseline median NT-proBNP level in the TYVASO group was 593 ng/L at baseline.5

ANSWER

300-1400 ng/L*:

Based on your patient’s NT-proBNP level, your patient may be at intermediate risk and a candidate for TYVASO.1,2 Consider re-evaluating NT-proBNP along with other important parameters of risk/prognosis every 3 to 6 months.

NT-proBNP is one of the assessments that can help predict long-term treatment outcomes.3-5 NT-proBNP is a proven prognostic factor (or predictor of risk) in US-based REVEAL and European observational studies.

 

*In TRIUMPH, baseline median NT-proBNP level in the TYVASO group was 593 ng/L at baseline.6

ANSWER

>1400 ng/L:

Based on your patient’s NT-proBNP level, your patient may be at high risk and may be appropriate for parenteral prostacyclin therapy.1,2 Patient could be considered for TYVASO if unwilling or unable to tolerate parenteral prostacyclin therapy.2 Consider re-evaluating NT-proBNP along with other important parameters of risk/prognosis every 3 to 6 months.

NT-proBNP is one of the assessments that can help predict long-term treatment outcomes.3-5 NT-proBNP is a proven prognostic factor (or predictor of risk) in US-based REVEAL and European observational studies.

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. [Published online ahead of print. Accessed July 19, 2019.] Chest. doi:10.1016/j.chest.2019.02.004.
  3. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2).
  4. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).
  5. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.

 

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. TYVASO [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2017.
  3. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. [Published online ahead of print. Accessed July 19, 2019.] Chest. doi:10.1016/j.chest.2019.02.004.
  4. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2).
  5. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).
  6. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565-586.
  3. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. [Published online ahead of print. Accessed July 19, 2019.] Chest. doi:10.1016/j.chest.2019.02.004.
  4. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2).
  5. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).

 

Question

1
2
3
4
5
6
slideslide

What is your patient’s NYHA/WHO Functional Class (FC)?

NYHA=New York Heart Association; WHO=World Health Organization.

|

ANSWER

FC I*:

Based on your patient’s NYHA/WHO FC, your patient may be at low risk.1 Consider re-evaluating NYHA/WHO FC along with other important parameters of risk/prognosis every 3 to 6 months.

NYHA/WHO FC is one of the assessments that can help predict long-term treatment outcomes.2-4 NYHA/WHO FC is a validated prognostic factor (or predictor of risk) in US-based REVEAL and European observational studies.

 

*In TRIUMPH, patients were NYHA FC III (98%) or IV (2%) at baseline.5

ANSWER

FC II*:

Based on your patient’s NYHA/WHO FC, your patient may be at low risk.1 Consider re-evaluating NYHA/WHO FC along with other important parameters of risk/prognosis every 3 to 6 months.

NYHA/WHO FC is one of the assessments that can help predict long-term treatment outcomes.2-4 NYHA/WHO FC is a validated prognostic factor (or predictor of risk) in US-based REVEAL and European observational studies.

 

*In TRIUMPH, patients were NYHA FC III (98%) or IV (2%) at baseline.5

ANSWER

FC III*:

Based on your patient’s NYHA/WHO FC, your patient may be at intermediate risk and a candidate for TYVASO.1,2 Consider re-evaluating NYHA/WHO FC along with other important parameters of risk/prognosis every 3 to 6 months.

Studies establishing the effectiveness of TYVASO enrolled predominantly FC III patients.2

NYHA/WHO FC is one of the assessments that can help predict long-term treatment outcomes.3-5 NYHA/WHO FC is a validated prognostic factor (or predictor of risk) in US-based REVEAL and European observational studies.

 

*In TRIUMPH, patients were NYHA FC III (98%) or IV (2%) at baseline.6

ANSWER

FC IV:

Based on your patient’s NYHA/WHO FC, your patient may be at high risk and may be appropriate for parenteral prostacyclin therapy.1,2 Patient could be considered for TYVASO if unwilling or unable to tolerate parenteral prostacyclin therapy.2 Consider re-evaluating NYHA/WHO FC along with other important parameters of risk/prognosis every 3 to 6 months.

NYHA/WHO FC is one of the assessments that can help predict long-term treatment outcomes.3-5 NYHA/WHO FC is a validated prognostic factor (or predictor of risk) in US-based REVEAL and European observational studies.

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. [Published online ahead of print. Accessed July 19, 2019.] Chest. doi:10.1016/j.chest.2019.02.004.
  3. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2).
  4. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).
  5. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. [Published online ahead of print. Accessed July 19, 2019.] Chest. doi:10.1016/j.chest.2019.02.004.
  3. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2).
  4. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).
  5. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. TYVASO [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2017.
  3. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. [Published online ahead of print. Accessed July 19, 2019.] Chest. doi:10.1016/j.chest.2019.02.004.
  4. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2).
  5. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).
  6. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565-586.
  3. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. [Published online ahead of print. Accessed July 19, 2019.] Chest. doi:10.1016/j.chest.2019.02.004.
  4. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2).
  5. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).

Question

1
2
3
4
5
6
slideslide

Is your patient in need of fast titration to achieve target dose?

|

ANSWER

Yes

Your patient may be a candidate for TYVASO. The average time to target dose on TYVASO is ~3 weeks.1,2

Target dose for TYVASO = 9 breaths, 4x daily.2

Evaluate important parameters of risk/prognosis to confirm if TYVASO is appropriate for your patient.

ANSWER

No

PAH is a progressive disease.1,2 Patients who are at intermediate risk and start TYVASO earlier may have better long-term outcomes (eg, 6MWD) than those who delay adding therapy for as little as 12 weeks.2 Your patient may be appropriate for TYVASO; the average time to target dose on TYVASO is ~3 weeks.3

Target dose for TYVASO = 9 breaths, 4x daily.4

Evaluate important parameters of risk/prognosis to confirm if TYVASO is appropriate for your patient.

References:

  1. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.
  2. TYVASO [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2017.

References:

  1. Vizza CD, Badagliacca R, Messick CR, et al. The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: a meta-analysis. Int J Cardiol. 2018;254:299-301.
  2. Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011;30(12):1327-1333.
  3. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.
  4. TYVASO [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2017.

Question

1
2
3
4
5
6
slideslide

Does your patient with intermediate risk factors have comorbid conditions* that make them not appropriate for oral prostacyclin-class medications?

*Such as gastrointestinal related conditions

|

ANSWER

Yes

Your patient may be a candidate for TYVASO if your patient is in NYHA/WHO FC III and has other risk factors consistent with intermediate-risk status.1,2

Evaluate important parameters of risk/prognosis to confirm if TYVASO is appropriate for your patient.

 

FC=functional class; NYHA=New York Heart Association; WHO=World Health Organization.

ANSWER

No

Your patient may still be a candidate for TYVASO if your patient is in NYHA/WHO FC III and has other risk factors consistent with intermediate-risk status.1,2

Evaluate important parameters of risk/prognosis to confirm if TYVASO is appropriate for your patient.

 

FC=functional class; NYHA=New York Heart Association; WHO=World Health Organization.

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. TYVASO [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2017.

References:

  1. Galiè N, Humbert M, Vachiery JL, et al; for ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2016;37(1):67-119.
  2. TYVASO [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2017.